Development of a highly stable and targetable nanoliposomal formulation of topotecan.
暂无分享,去创建一个
Ceirin M. Connolly-Ingram | C. Benz | B. Hann | John W. Park | J. Marks | B. Liu | D. Drummond | C. Noble | M. Hayes | D. Kirpotin | K. Hong | Zexiong Guo | B. S. Gabriel | Bianca S. Gabriel
[1] C. Benz,et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine , 2009, Cancer Chemotherapy and Pharmacology.
[2] John W. Park,et al. Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine , 2009, Journal of Pharmacology and Experimental Therapeutics.
[3] John W. Park,et al. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. , 2008, Journal of pharmaceutical sciences.
[4] Jianwei Zhu,et al. Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification , 2008, Biotechnology progress.
[5] T. Herzog,et al. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma , 2008, Expert review of anticancer therapy.
[6] M. Bally,et al. Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors , 2008, Clinical Cancer Research.
[7] S. Strychor,et al. Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts , 2007, Clinical Cancer Research.
[8] S. Nicum,et al. Topotecan for the treatment of small-cell lung cancer , 2007, Expert review of anticancer therapy.
[9] Jennifer I. Hare,et al. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. , 2006, Anti-cancer agents in medicinal chemistry.
[10] Anitha Thomas,et al. Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation , 2006, Pharmaceutical Research.
[11] R. Pazdur,et al. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. , 2006, Oncology.
[12] M. Bally,et al. Copper-topotecan complexation mediates drug accumulation into liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[13] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[14] M. Berger,et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. , 2006, Neuro-oncology.
[15] X Zhang,et al. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug‐resistant leukaemia cells in vitro and xenograft in mice , 2006, European journal of clinical investigation.
[16] John W. Park,et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. , 2006, Cancer research.
[17] M. Berger,et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. , 2006, Cancer research.
[18] P. van Hoogevest,et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[19] D. Spriggs,et al. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. , 2005, The oncologist.
[20] C. Benz,et al. Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes , 2005, Clinical Cancer Research.
[21] Corrie Lynn Messerer,et al. Liposomal Irinotecan , 2004, Clinical Cancer Research.
[22] C. Benz,et al. Development of ligand-targeted liposomes for cancer therapy , 2004, Expert opinion on therapeutic targets.
[23] K. Edwards,et al. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[24] Imran Ahmad,et al. Development and characterization of a novel liposome-based formulation of SN-38. , 2004, International journal of pharmaceutics.
[25] T. Allen,et al. Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.
[26] Udo Greiser,et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. , 2003, Cancer research.
[27] Ulrik B Nielsen,et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.
[28] Bradley D. Anderson,et al. Stable Supersaturated Aqueous Solutions of Silatecan 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin via Chemical Conversion in the Presence of a Chemically Modified β-Cyclodextrin , 2002, Pharmaceutical Research.
[29] F. Chang,et al. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation , 2002, Anti-cancer drugs.
[30] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] S. Guichard,et al. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] M. Bally,et al. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. , 2000, Cancer research.
[33] D. Baccanari,et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[35] A. Kuin,et al. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. , 1997, Cancer research.
[36] L. Grochow,et al. An overview of the clinical pharmacology of topotecan. , 1997, Seminars in oncology.
[37] Dayan Ad. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). , 1996 .
[38] N. Palepu,et al. Preformulation studies to aid in the development of a ready-to-use injectable solution of the antitumor agent, topotecan , 1996 .
[39] X. Gao,et al. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. , 1994, Journal of pharmaceutical sciences.
[40] V. Stella,et al. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. , 1992, Journal of pharmaceutical sciences.
[41] C. Osborne,et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.
[42] W. J. Dyer,et al. A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.
[43] G. R. Bartlett. Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.
[44] H. Maeda,et al. Macromolecular Therapeutics , 2003, Clinical pharmacokinetics.
[45] Yechezkel Barenholz,et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.
[46] J. Waldrep,et al. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice , 1999, Cancer Chemotherapy and Pharmacology.
[47] B. Giovanella,et al. Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice , 1999, Cancer Chemotherapy and Pharmacology.
[48] J. Verweij,et al. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. , 1997, British Journal of Cancer.
[49] M. Muller,et al. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. , 1995, Oncology research.
[50] J. Beijnen,et al. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. , 1990, Journal of pharmaceutical and biomedical analysis.